Genmab A/S (NASDAQ:GMAB) Shares Purchased by Two Sigma Investments LP

Two Sigma Investments LP increased its stake in Genmab A/S (NASDAQ:GMAB - Free Report) by 122.2% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,706,364 shares of the company's stock after purchasing an additional 938,455 shares during the quarter. Two Sigma Investments LP owned 0.26% of Genmab A/S worth $35,612,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Tema Etfs LLC purchased a new stake in shares of Genmab A/S in the 4th quarter worth about $1,230,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Genmab A/S in the fourth quarter valued at about $60,000. Point72 Asset Management L.P. purchased a new stake in shares of Genmab A/S in the fourth quarter valued at about $1,840,000. Point72 Hong Kong Ltd acquired a new stake in shares of Genmab A/S in the fourth quarter valued at approximately $911,000. Finally, Quantinno Capital Management LP increased its stake in shares of Genmab A/S by 273.2% during the 4th quarter. Quantinno Capital Management LP now owns 90,335 shares of the company's stock worth $1,885,000 after purchasing an additional 66,128 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Leerink Partnrs upgraded Genmab A/S from a "hold" rating to a "strong-buy" rating in a report on Thursday, February 13th. BNP Paribas upgraded Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Tuesday, February 11th. Sanford C. Bernstein lowered Genmab A/S from a "market perform" rating to an "underperform" rating in a research note on Tuesday, April 1st. Truist Financial cut their target price on shares of Genmab A/S from $50.00 to $45.00 and set a "buy" rating for the company in a research note on Tuesday, March 11th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $37.00 price target (down from $50.00) on shares of Genmab A/S in a research note on Wednesday, April 9th. One analyst has rated the stock with a sell rating, three have issued a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Genmab A/S has a consensus rating of "Moderate Buy" and an average price target of $39.17.

Genmab A/S Stock Down 1.0%

Shares of GMAB traded down $0.22 during mid-day trading on Monday, hitting $20.81. The company had a trading volume of 1,247,688 shares, compared to its average volume of 1,131,782. Genmab A/S has a 1-year low of $17.24 and a 1-year high of $28.96. The business's 50-day simple moving average is $19.77 and its 200-day simple moving average is $20.67. The stock has a market cap of $13.34 billion, a PE ratio of 11.96, a P/E/G ratio of 2.65 and a beta of 1.04.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.31 earnings per share for the quarter, beating analysts' consensus estimates of $0.23 by $0.08. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. The company had revenue of $715.00 million for the quarter, compared to analyst estimates of $5.17 billion. On average, sell-side analysts expect that Genmab A/S will post 1.45 earnings per share for the current year.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.